In ER+/LN- breast cancer patients with endocrine monotherapy, it was found that the worse the clinical stage and differentiation of tumor and the prognosis of patients, the higher is the amount of JMJD6 protein; loss or knockdown of JMJD6 inhibited the progression of breast cancer via regulating the TGF-β pathway (34). This evidence concerns the gene JMJD6 and breast carcinoma.